| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1052 | 2013 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 675 | 2019 |
| Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study L Rosiñol, A Oriol, AI Teruel, D Hernández, J López-Jiménez, ... Blood, The Journal of the American Society of Hematology 120 (8), 1589-1596, 2012 | 583 | 2012 |
| Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study MV Mateos, JM Hernández, MT Hernández, NC Gutiérrez, L Palomera, ... Blood 108 (7), 2165-2172, 2006 | 544 | 2006 |
| Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and … BB Bjorkstrand, P Ljungman, H Svensson, J Hermans, A Alegre, ... | 457 | 1996 |
| Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are … JJ Lahuerta, MV Mateos, J Martínez-López, L Rosinol, A Sureda, ... Journal of Clinical Oncology 26 (35), 5775-5782, 2008 | 360 | 2008 |
| High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation … B Paiva, NC Gutiérrez, L Rosiñol, MB Vídriales, MÁ Montalbán, ... Blood, The Journal of the American Society of Hematology 119 (3), 687-691, 2012 | 341 | 2012 |
| Depth of response in multiple myeloma: a pooled analysis of three PETHEMA/GEM clinical trials JJ Lahuerta, B Paiva, MB Vidriales, L Cordón, MT Cedena, N Puig, ... Journal of Clinical Oncology 35 (25), 2900-2910, 2017 | 327 | 2017 |
| Long-term prognostic significance of response in multiple myeloma after stem cell transplantation J Martinez-Lopez, J Blade, MV Mateos, C Grande, A Alegre, ... Blood, The Journal of the American Society of Hematology 118 (3), 529-534, 2011 | 257 | 2011 |
| Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study J García-Suárez, J de la Cruz, Á Cedillo, P Llamas, R Duarte, ... Journal of hematology & oncology 13, 1-12, 2020 | 249 | 2020 |
| The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma R García-Sanz, JR González-Porras, JM Hernandez, M Polo-Zarzuela, ... Leukemia 18 (4), 856-863, 2004 | 220 | 2004 |
| Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high-dose cyclophosphamide plus GM-CSF vs G-CSF alone A Alegre, JF Tomas, C Martinez-Chamorro, JJ Gil-Fernandez, ... Bone Marrow Transplantation 20 (3), 211-217, 1997 | 178 | 1997 |
| The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function M Dimopoulos, A Alegre, EA Stadtmauer, H Goldschmidt, JA Zonder, ... Cancer 116 (16), 3807-3814, 2010 | 172 | 2010 |
| Are myeloma patients with renal failure candidates for autologous stem cell transplantation? JF San Miguel, JJ Lahuerta, R Garcia-Sanz, A Alegre, J Blade, R Martinez, ... The Hematology Journal: the Official Journal of the European Haematology …, 2000 | 147 | 2000 |
| Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients JJ Lahuerta, J Martinez‐Lopez, J Serna, J Bladé, C Grande, A Alegre, ... British Journal of Haematology: TRANSPLANTATION 109 (2), 438-446, 2000 | 144 | 2000 |
| Desarrollo de un programa de educación nutricional y valoración del cambio de hábitos alimentarios saludables en una población de estudiantes de Enseñanza Secundaria Obligatoria M Martínez, MD Hernández, M Ojeda, R Mena, A Alegre, JL Alfonso Nutrición Hospitalaria 24 (4), 504-510, 2009 | 142 | 2009 |
| Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma … L Rosinol, A Oriol, MV Mateos, A Sureda, P García-Sánchez, N Gutiérrez, ... Journal of Clinical Oncology 25 (28), 4452-4458, 2007 | 142 | 2007 |
| Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma PG Richardson, A Oriol, A Larocca, J Bladé, M Cavo, P Rodriguez-Otero, ... Journal of Clinical Oncology 39 (7), 757-767, 2021 | 140 | 2021 |
| Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression MV Mateos, JM Hernandez, MT Hernandez, NC Gutierrez, L Palomera, ... Haematologica 93 (4), 560-565, 2008 | 136 | 2008 |
| Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem … N Kröger, JA Perez-Simon, H Myint, H Klingemann, A Shimoni, A Nagler, ... Biology of Blood and Marrow Transplantation 10 (10), 698-708, 2004 | 132 | 2004 |
